Office Location: 3000 Western Ave, Seattle, WA 98121
Accepting Students to Lab: No
- PhD in molecular biology, University of Wisconsin
- BA with great distinction in biochemistry, University of California, Berkeley
- Viral pathogenesis
- Vaccine research and design
- Non-human primate models for AIDS
- Pharmaceutics 533: Biopharmaceutics and Drug Delivery
- Pharmaceutics 586: Pharmaceutical Biotechnology
- Conjoint 543: Vaccines
Dr. Shiu-Lok Hu obtained his B.A. degree in Biochemistry from the University of California, Berkeley, Ph. D. degree in Molecular Biology from the University of Wisconsin, Madison, and post-doctoral training in tumor virology in Cold Spring Harbor Laboratory. He started working on HIV/AIDS in 1985 when he joined a biotech company in Seattle, which later became a part of the Bristol-Myers Squibb Pharmaceutical Research Institute. During this time (1985-1997), he developed the first recombinant virus as a candidate HIV vaccine for FDA-approved clinical trials and provided the first demonstration of vaccine protection against SIV infection in a macaque model by the “poxvirus prime-protein boost” immunization strategy.
Dr. Hu joined the faculty at the University of Washington, Seattle, in 1997. He is currently Professor of Pharmaceutics and Adjunct Professor of Microbiology. His research focuses on the design of immunogens to elicit broadly neutralizing antibodies against HIV-1, characterizing the targets and mechanisms of protective immunity against primate lentiviruses, and factors that contribute to the resistance or adaptation of lentiviruses in primate species.